Enliven Therapeutics, Inc.
NASDAQ:ELVNBiotechnology
Healthcare
$46.41 -0.27%
-$0.12 today
- Market cap
- $3.42B
- Beta
- 0.40
- P/E (TTM)
- -28.4
- EPS (TTM)
- -$1.57
52W Low $14.79High $48.53
Volume 0.99M
Average 1.35M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$119.66M
FY 2025 · Annual
Net Income
-$103.69M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 263K |
| Gross Profit | 0 | 0 | 0 | 0 | (263K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 20.47M | 31.02M | 64.57M | 80.78M | 85.86M |
| Selling, General & Admin | 4.29M | 7.77M | 18.96M | 23.78M | 33.8M |
| Operating Expenses | 24.76M | 38.79M | 83.53M | 104.55M | 119.4M |
| Depreciation & Amortization | 115K | 215K | 297K | 317K | 263K |
| EBITDA | (24.63M) | (37.45M) | (71.29M) | (88.48M) | (103.43M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (24.76M) | (38.79M) | (83.53M) | (104.55M) | (119.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 22K | 1.13M | 11.97M | 14.89M | 16.01M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 22K | 1.13M | 11.95M | 15.76M | 15.96M |
| Income Before Tax | (24.74M) | (37.66M) | (71.58M) | (88.79M) | (103.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 232K | 0 |
| Net Income | (24.74M) | (37.66M) | (71.58M) | (89.02M) | (103.69M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.17) | (6.03) | (2.01) | (1.89) | (1.83) |
| EPS (Diluted) | (3.17) | (6.03) | (2.01) | (1.89) | (1.83) |
| 7.81M | 6.25M | 35.55M | 47.07M | 56.66M | |
| 7.82M | 6.25M | 35.55M | 47.07M | 56.66M |
ELVN Earnings Waterfall · TTM
NASDAQ:ELVN · Revenue to Net Income
Key Ratios
EPS$-1.68
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-23.0
P/S Ratio0.0
Analysis
$0 of revenue converted into -$113.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.68, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 21, 2026 |
How much revenue does ELVN generate?
Enliven Therapeutics, Inc. (ELVN) reported $0.00 of revenue in fiscal 2025.
Is ELVN profitable?
Enliven Therapeutics, Inc. (ELVN) reported -$103.69M of net income.
Continue the stock analysis
Jump to another research area for this company.